Eisai/Biogen’s Leqembi Will See Broadened Access To Majority Of Patients

Full Approval For Alzheimer’s Triggers CMS Coverage

CMS will cover Leqembi now that the US FDA has converted Leqembi’s accelerated approval to traditional approval, giving most patients eligible for treatment access to the drug. Updated labeling puts greater emphasis on safety concerns.

Geriatric doctor consults with Alzheimer's patient
Leqembi's updated label has new language for prescribers on safety • Source: Shutterstock

Eisai Co., Ltd. and its partner Biogen, Inc. can proceed with the full commercial launch of Leqembi (lecanemab) now that the Alzheimer’s drug has received full approval from the US Food and Drug Administration, and since the Centers for Medicare and Medicaid Services (CMS) confirmed a commitment it made in June to provide Medicare coverage for anti-amyloid therapies granted full approval.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

Leqembi Launch Set For Germany And Austria As EU Approval Finally Comes

 

Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch: 13 Approvals And 13 Phase III Trial Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Vanrafia Approval Plays Into Novartis’s Multipronged IgAN Approach

 

The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.

More from Scrip

The 2025 Scrip Awards Is Open For Entries

Entries for the Scrip Awards are now open. Now in their 21st year, the Awards seek to reward the outstanding achievements of the pharmaceutical, biotech and allied industries in improving human health.

US-China Tariff War Pressures Pharma’s Complex Supply Chain

 
• By 

Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, Scrip hears.

AstraZeneca Logs Japan Growth Despite Price Cuts

 
• By 

AstraZeneca logs growth in Japan despite a big reimbursement price cut for one of its top sellers and expects 40 approvals in the country over the next six years.